Zeidan, Amer M.
Yale Cancer Center · Yale University
4 papers on CoChatORCID 0000-0001-7017-8160
Most cited papers
- Verified
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Zeidan, A. M., Wang, R., Wang, X., Shallis, R. M., Podoltsev, N. A., Bewersdorf, J. P., Huntington, S. F., Neparidze, N., Giri, S., Gore, S. D., et al. (2020) · Blood Advances
Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes
Cited by 93
- Verified
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes
Zeidan, A. M., Boss, I., Beach, C. L., Copeland, W. B., Thompson, E., Fox, B. A., Hasle, V. E., Ogasawara, K., Cavenagh, J., Silverman, L. R., et al. (2022) · Blood Advances
Acute Myeloid Leukemia ResearchCancer Immunotherapy and Biomarkers
Cited by 61
- Verified
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Badar, T., Nanaa, A., Atallah, E., Shallis, R. M., Guilherme, S. D. C. C., Goldberg, A. D., Saliba, A. N., Patel, A., Bewersdorf, J. P., DuVall, A. S., et al. (2024) · Blood Cancer Journal
Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes
Cited by 33
- Verified
The conundrum of drug development in higher-risk MDS: Lessons learned from recently failed phase 3 clinical trials
Stahl, M., & Zeidan, A. M. (2026) · Blood
Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes
Cited by 14
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free